Sector News

Valeant's debt-fueled castoffs continue with half-priced Obagi sale

July 17, 2017
Life sciences

It’s been more than a year since analysts first said Valeant could sell off its Obagi Medical Products business to raise cash, but the Canadian drugmaker has finally found a taker.

An investment fund has agreed to fork over $190 million for the dermatology business, which Valeant grabbed in 2013. The drugmaker will use that money to pay down the M&A-fueled debt mountain that’s been worrying investors and holding down shares.

“The sale of Obagi marks additional progress in our efforts to streamline our operations and reduce debt,” Valeant CEO Joseph Papa said in a statement announcing the sale to Haitong International Zhonghua Finance Acquisition Fund I.

Longtime Valeant critic David Maris, however, was quick to point out that Valeant is selling Obagi for half the sum it originally spent on the buy; the $190 million sale price falls 56.5% below the $437 million Valeant handed over to acquire it, he wrote in a Monday note to clients.

And while Valeant “continues to make progress toward its asset sales and total debt reduction targets,” the way Maris sees it, its efforts so far haven’t been enough.

For all of Papa’s talk of asset sales, Valeant has only pulled off a few. Late 2016 talks with Takeda over a potential $10 billion sale of its gastrointestinal unit Salix fell through, and a rumored divestment of eyecare giant Bausch & Lomb hasn’t yet materialized. Before the Obagi announcement, the company had managed just a $2.1 billion sale of cancer vaccine maker Dendreon and some skincare brands, along with a $930 million sale of iNova Pharmaceuticals.

“In our opinion, leverage remains high and we do not believe that recent deals … have had a significant deleveraging impact,” Maris wrote.

Valeant hasn’t been relying on castoffs to pay down its debt, though. Last week, it said it would redeem $500 million in senior notes, bringing its debt reduction tally to $4.8 billion since the end of 2016’s Q1.

Of course, debt is far from Valeant’s only problem. The company has suffered under struggling sales, a slew of investigations and price-hike pushback in addition to the debt-default worries.

By Carly Helfand

Source: Fierce Pharma

Related News

February 28, 2021

UCB taps Microsoft to accelerate drug discovery, clinical trials

Life sciences

The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.

February 28, 2021

GSK to close two UK antibiotics manufacturing sites

Life sciences

The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.

February 28, 2021

Colorcon launches TiO2-free supplement coating

Life sciences

“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.

Send this to a friend